Letters to the Editor

Lambert, Lieh-bang Liou, MD, PhD,
rheumatologist,
Chang Gung Memorial Hospital,
Lin-kou Medical Center,
Tao-yuan, Taiwan

Correction

“Disappearing Dollars,” (October 2007 TR, p. 14), stated: “The ACR supports a proposal to triple NIH funding for FY 2008 and provide annual increases to the NIAMS budget, and opposes the use of budgetary mechanisms that arbitrarily limit research funding.”

To clarify, the ACR supported tripling the percentage requested of NIH funding—not the entire NIH budget.

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets

Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

Correction

Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

Updates on Giant Cell Arteritis

Giant Cell Arteritis Challenging to Diagnose, Manage

Case Report: Giant Cell Arteritis-Related Stroke

Correction

Related Articles